Back to Search
CALLIE O'BRYANT, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1912757063Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (19)
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
PMID 18509645·Cancer Chemother Pharmacol·2009
8-other
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
PMID 18618082·Invest New Drugs·2009
3-trial
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
PMID 19652058·J Clin Oncol·2009
3-trial
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
PMID 18320191·Cancer Chemother Pharmacol·2008
3-trial
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
PMID 18058098·Cancer Chemother Pharmacol·2008
3-trial
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
PMID 18043132·Anticancer Drugs·2008
3-trial
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
PMID 19074845·Mol Cancer Ther·2008
3-trial
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
PMID 18719068·J Oncol Pharm Pract·2008
8-other
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
PMID 18579665·Clin Cancer Res·2008
3-trial
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
PMID 17693653·Ann Oncol·2007
3-trial
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
PMID 17404091·Clin Cancer Res·2007
3-trial
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
PMID 17000682·Clin Cancer Res·2006
3-trial
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
PMID 16980604·Ann Oncol·2006
3-trial
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
PMID 15906031·Cancer Chemother Pharmacol·2005
3-trial
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
PMID 15534096·Clin Cancer Res·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 625 19TH ST S
BIRMINGHAM, AL 35233 - Phone
- (205) 934-3640
Quick Facts
- NPI
- 1912757063
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 19
Are you this provider?
Claim Your Profile